Abstract 119P
Background
Waiting for the highest pCR is clinically relevant as this helps to choose the candidates for a watch–and–wait approach or local excision, identify the optimal operation timing, increase the chance of R0 resection, or improve disease–free survival and/or overall survival. Meanwhile, LR is a serious problem since it causes disabling symptoms, and successful salvage of pelvic recurrence is rarely possible. Therefore, this paper will investigate the impacts of dose fractionations of preoperative radiotherapy (RT) on pCR and LR for rectal cancer using three– or four–field conformal RT techniques.
Methods
The PubMed, Embase, and Web of Science databases (2000 to May 2018) were systematically searched for evidence. To evaluate the dose–response relationship, logistic response curves were fitted for pCR values, and the linear regression model was fitted for risk reduction of LR as a function of biologic effective dose (BED).
Results
Data from 8 comparative studies enrolling 14,869 patients were analyzed for pCR. Higher radiation doses were associated with increased pCR. If pCR curve was fitted using BED as a covariate, the dose required for 50% response (D50) ranged from 68·3 to 108·0 Gy. If BED was corrected with RT overall treatment time, The pCR curves of the similar treatment regimens in special patient cohorts interacted at identical D50, 50.7, 59.0, or 70.9 Gy. Regarding LR risk, 31 studies were identified and yielded 7,699 patients. Increasing RT doses was also associated with reduction in LR, and a linear dose–response effect of BED was seen on the risk reduction of LR. Each 1 Gy increase in BED would reduce LR by 1·36%, hence a hypothesis was proposed that a BED of approximately 73.5 Gy would need to achieve 100% LC.
Conclusions
Higher radiation doses were associated with increased pCR and LR reduction. In the future, by means of dose–response curves and the available pCR and LR values, we could perhaps obtain the dose gap to achieve 50% pCR response and 100% LC, and predict the amplitude of clinical benefits through limited RT dose escalation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract